JP2007509106A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509106A5
JP2007509106A5 JP2006536068A JP2006536068A JP2007509106A5 JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5 JP 2006536068 A JP2006536068 A JP 2006536068A JP 2006536068 A JP2006536068 A JP 2006536068A JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pyridinyl
pyrimidinyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536068A
Other languages
English (en)
Japanese (ja)
Other versions
JP4827737B2 (ja
JP2007509106A (ja
Filing date
Publication date
Priority claimed from GBGB0325031.3A external-priority patent/GB0325031D0/en
Application filed filed Critical
Publication of JP2007509106A publication Critical patent/JP2007509106A/ja
Publication of JP2007509106A5 publication Critical patent/JP2007509106A5/ja
Application granted granted Critical
Publication of JP4827737B2 publication Critical patent/JP4827737B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536068A 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用 Expired - Fee Related JP4827737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0325031.3 2003-10-27
GBGB0325031.3A GB0325031D0 (en) 2003-10-27 2003-10-27 Organic compounds
PCT/EP2004/012080 WO2005039586A1 (en) 2003-10-27 2004-10-26 Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders

Publications (3)

Publication Number Publication Date
JP2007509106A JP2007509106A (ja) 2007-04-12
JP2007509106A5 true JP2007509106A5 (enExample) 2007-12-13
JP4827737B2 JP4827737B2 (ja) 2011-11-30

Family

ID=29725439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536068A Expired - Fee Related JP4827737B2 (ja) 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用

Country Status (4)

Country Link
US (1) US7687512B2 (enExample)
JP (1) JP4827737B2 (enExample)
GB (1) GB0325031D0 (enExample)
WO (1) WO2005039586A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083477A2 (en) 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
PT1843771E (pt) * 2005-01-28 2011-12-02 Novartis Ag Uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação da atividade da cinase tie-2
ES2593319T3 (es) * 2005-05-02 2016-12-07 Novartis Ag Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
RU2450814C2 (ru) 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2166858A4 (en) 2007-06-07 2011-08-03 Intra Cellular Therapies Inc NEW HETEROCYCLIC COMPOUNDS AND ITS USE
JP5559043B2 (ja) * 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
WO2009036066A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
KR20110053354A (ko) * 2008-08-13 2011-05-20 노파르티스 아게 폐동맥 고혈압의 치료
US20110243957A1 (en) * 2008-09-24 2011-10-06 University Of South Florida Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
HRP20120793T1 (hr) 2008-11-05 2012-12-31 Teva Pharmaceutical Industries Ltd. Kristalni oblici nilotinib hci
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
JP5733839B2 (ja) * 2010-03-26 2015-06-10 国立大学法人北海道大学 神経変性疾患治療薬
ES2573831T3 (es) 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
EP3275440B1 (en) 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
CN105030776A (zh) * 2015-06-24 2015-11-11 北京键凯科技有限公司 Src蛋白抑制剂在制备预防和/治疗阿尔兹海默病药物中的应用
CN106905298A (zh) * 2015-12-22 2017-06-30 江苏先声药业有限公司 盐酸尼洛替尼杂质的制备方法
WO2018148533A1 (en) 2017-02-09 2018-08-16 Georgetown University Compositions and methods for treating lysosomal storage disorders
CN110769828A (zh) * 2017-05-12 2020-02-07 香港科技大学 作为epha4抑制剂的杂环化合物
US12559470B2 (en) 2018-09-13 2026-02-24 University Of Southern California FGFR inhibitors and uses thereof
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
AU2020232755A1 (en) * 2019-03-05 2021-11-04 Hongyi & Associates LLC. Compounds for treating neurodegenerative diseases and cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
DE69429078T2 (de) 1993-10-01 2002-07-11 Novartis Ag, Basel Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
EP1469810A4 (en) * 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP4827737B2 (ja) アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用
CN1960731B (zh) 调节炎性和转移过程的方法
AU2001248324B2 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2009017455A1 (en) A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
AU2016216636B2 (en) Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
JP2011530607A5 (enExample)
JP2024532374A (ja) Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
JP2009542638A5 (enExample)
JP2007523181A5 (enExample)
HUP0202399A2 (hu) Dopamin D3 receptor ligandumok alkalmazása veseelégtelenség kezelésére szolgáló gyógyszerek előállítására
JP2009532438A5 (enExample)
RU2304436C2 (ru) Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям
AU2020229558A1 (en) Combinational medication
WO2018216705A1 (ja) 神経変性疾患の予防及び／又は治療剤
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
TWI565466B (zh) 由α－碳酸酐酶之異形體調節之哺乳動物之疾病之治療
JP2009537606A5 (enExample)
RU2008127264A (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
BRPI0710496A2 (pt) combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2
JP5936821B2 (ja) チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法
AU2011202833B2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
CN116829548A (zh) 作为c-abl抑制剂的吡唑衍生物
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合